Immunovia AB is a diagnostic company with the mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates with healthcare providers, leading experts and patient advocacy groups globally to make this test available to individuals at high risk for pancreatic cancer.
Immunovia invests extensively in science and has conducted a number of studies to develop and validate the accuracy of its pancreatic cancer detection tests. These studies have been conducted at over thirty hospitals throughout the United States and Europe and have involved over 10,000 patients.
USA is the world’s largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
Immunovia has been a listed company since 2015, with shares traded (as IMMNOV) on Nasdaq First North in Stockholm and since 3 April 2018 traded on Nasdaq Stockholm. The company is headquartered in Lund, Sweden.
